The activity of target nucleases is a hallmark of infections and other diseases that can be detected by designing specific and highly sensitive oligonucleotide probes that generate a response/signal when cleaved by the enzyme.
The detection of nuclease activity is the differential element that SOMAprobes exploits to develop its oligonucleotide probes. These probes are versatile and can be implemented on standard immunoassay platforms including lateral flow, point-of-care devices, and mid- and high-throughput platforms present in every hospital laboratory.
Rapid test for detection of active infections with Coronavirus, among which SARS-Cov-2 and all circulating variants.
How does NuCor work?
Oligonucleotide cleavage detection
INTERPRETATION OF RESULTS
A coloured line appears in the Control line region (C) and none in the Test line region (T). This result means that the test has identified the presence of coronavirus nuclease activity, thus there is very high probability of active infection with SARS-CoV-2.
Two coloured lines appear, one in the Control (C) region and one in the Test (T) region. This result means that there is no detectable coronavirus nuclease activity, thus no active infection with SARS-CoV-2 present.
NuSep is a test that can rapidly detect a specific enzymatic (nuclease) activity present in an infected blood sample (sepsis), by the degradation of a specific nucleic acid substrate probe. This nuclease activity is used as biomarker of host response to an infection.
How does NuSep work?
Sampling one drop of blood
Nuclease activity reaction
Fast and easy results by immunoassay platforms
(LFA and CLIA)
In the global battle against bacterial resistance, SOMAprobes positions itself at the forefront, by creating an innovative approach that is harnessing bacteria’s own strategic arsenal for virulence in order to detect their presence and their antibiotic resistance.
SOMAprobes has made its mission to develop a revolutionary bacteria detection panel, NosoPlex, able to rapidly and robustly detect 5 of the most aggressive pathogens and their antibiotic resistance in less than 1 hour, directly from the clinical samples.
The panel test will be able to detect S. aureus (MSSA and MRSA) and 4 other most common causative bacteria of nosocomial respiratory infections with the comparable specificity and sensitivity parameters to the bacteria quantitative culture. The added diagnostic value of SOMAprobes panel test is represented by the innovative capability of simultaneously detecting 5 bacteria and their resistance to β-lactam antibiotics (e.g. methicillin, the most frequently used antibiotic) from non-invasive respiratory samples (endotracheal aspirates). Due to its simple-but-effective strip format, this test can be easily performed in situ, without the need for specialised lab equipment or highly qualified personnel.